Lisata Therapeutics (NASDAQ:LSTA) Stock Price Up 2.5%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) rose 2.5% during mid-day trading on Thursday . The stock traded as high as $2.86 and last traded at $2.85. Approximately 1,130 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 13,442 shares. The stock had previously closed at $2.78.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research note on Friday, March 1st.

Lisata Therapeutics Stock Up 2.5 %

The firm has a market cap of $23.67 million, a PE ratio of -1.10 and a beta of 1.04. The business has a 50 day simple moving average of $3.03 and a two-hundred day simple moving average of $2.69.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Thursday, February 29th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.20. Equities analysts forecast that Lisata Therapeutics, Inc. will post -3.08 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. acquired a new position in Lisata Therapeutics in the third quarter valued at approximately $817,000. Renaissance Technologies LLC acquired a new position in Lisata Therapeutics in the 3rd quarter worth about $467,000. BlackRock Inc. purchased a new position in Lisata Therapeutics during the third quarter worth approximately $263,000. State Street Corp acquired a new stake in Lisata Therapeutics in the third quarter valued at approximately $66,000. Finally, Citadel Advisors LLC acquired a new stake in Lisata Therapeutics in the second quarter valued at approximately $64,000. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.